SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Jindřich Činátl, Dominique Thomas et al.|Nature Medicine|2016Cited by 185
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Rainer Hamacher, Christoph E. Heilig et al.|Journal of Nuclear Medicine|2025Cited by 10